Arrowhead Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding


Los Angeles, CA Indonesia
Total Funding:N/A
Lead Investor(s):N/A

City Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Arrowhead Pharmaceuticals's estimated annual revenue is currently $23.1M per year.
  • Arrowhead Pharmaceuticals received $52.5M in venture funding in January 2018.
  • Arrowhead Pharmaceuticals's estimated revenue per employee is $187,927

Employee Data

  • Arrowhead Pharmaceuticals has 123 Employees.
  • Arrowhead Pharmaceuticals grew their employee count by 12% last year.
  • Arrowhead Pharmaceuticals currently has 23 job openings.

Executive Contacts

Patrick ShaoDirector
Debbie BellSenior Director Safety Operations
Tao PeiSenior Director of Chemistry
Diamond MartinAssociate Director, Clinical Operations
Dawn ChristiansonDirector of Program Management
Jane DavidsonVice President, Administration
Caroline LaplacaExecutive Director Clinical Operations
Thomas SchluepVP Program Management
Vincent AnzaloneVice President, Finance and Investor Relations
Christine WooddellDirector, Liver Targeting

Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. Our Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The TRiM platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety. Our employees are nimble, science-driven, and innovative professionals. A career at Arrowhead offers the opportunity to collaborate with top notch scientists to rapidly discover and develop RNAi-based therapeutics to add to our growing pipeline. Research and development activities are located in Madison, WI. Our R&D group includes fully-integrated capabilities for chemistry, biology, and toxicology. Madison is an exciting and sophisticated city that includes state government, the flagship campus of the University of Wisconsin, and major research organizations. Our HQ, clinical and regulatory operations are located in Pasadena, CA. Just north of Los Angeles and resting in the foothills of the San Gabriel Mountains, Pasadena is known for its natural scenic beauty, vibrant cultural and academic environment and rich architectural setting.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
Rancho BioScien...
Tlc Pharmacy
Otsuka America
endpoint Clinic...
ZO Skin Health
Teledyne Hanson...

Arrowhead Pharmaceuticals News

09/03/2019 - Arrowhead Pharmaceuticals and three other stocks to watch

Arrowhead Pharmaceuticals Inc. ARWR, -1.04% jumped $1.44 to $34.36 on 1.18 million shares traded Wednesday. The company announced ...

09/08/2019 - Is Arrowhead Pharmaceuticals Inc (ARWR)’s Recently Published U.S. Patent Application A Blockbuster?

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) business model of going after extrahepatic targets and establishing first mover advantage ...

09/03/2019 - Arrowhead Pharmaceuticals to Participate in Upcoming ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate ...

Arrowhead Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2016-08-10$45.0MUndisclosedCantor Fitzgerald & CoArticle
2017-01-12$9.6MUndisclosedSilence TherapeuticsArticle
2018-01-19$52.5MUndisclosedJefferies LLCArticle